BACKGROUND: Oncology patients are more at risk for drug related problems because of treatment with (combinations of) anticancer drugs, as they have a higher risk for organ failure or altered metabolism with progression of their disease. OBJECTIVE: The aim of this study was to characterize and to evaluate the frequency of potential drug related problems (pDRPs) among oncology patients. SETTING: Outpatient- and day-care centres for Internal and Pulmonary Medicine at the Deventer Hospital, Deventer, The Netherlands. METHOD: A prospective, descriptive, observational study was carried out from March 2010 to March 2011 at the Deventer Hospital, Deventer, The Netherlands. All patients older than 18 years receiving anticancer drugs prescribed by an internal medicineoncologist or pulmonologist-oncologist were included. MAIN OUTCOME MEASURE: The primary outcome was the number and type of pDRPs according to Dutch guidelines. RESULTS: Among 546 patients with cancer, 952 pDRPs were identified, of which 474 were oncology-related. These were mainly drug interactions (IA) (246 IA in 157 patients) and potential contraindications (pCI) (201 pCI in 143 patients). CONCLUSION: Most identified pDRPs in cancer patients were IAs and pCIs and involved corticosteroids. The most frequently occurring oncology-related IAs were classified as minor or moderate levels of severity.
BACKGROUND: Oncology patients are more at risk for drug related problems because of treatment with (combinations of) anticancer drugs, as they have a higher risk for organ failure or altered metabolism with progression of their disease. OBJECTIVE: The aim of this study was to characterize and to evaluate the frequency of potential drug related problems (pDRPs) among oncology patients. SETTING:Outpatient- and day-care centres for Internal and Pulmonary Medicine at the Deventer Hospital, Deventer, The Netherlands. METHOD: A prospective, descriptive, observational study was carried out from March 2010 to March 2011 at the Deventer Hospital, Deventer, The Netherlands. All patients older than 18 years receiving anticancer drugs prescribed by an internal medicineoncologist or pulmonologist-oncologist were included. MAIN OUTCOME MEASURE: The primary outcome was the number and type of pDRPs according to Dutch guidelines. RESULTS: Among 546 patients with cancer, 952 pDRPs were identified, of which 474 were oncology-related. These were mainly drug interactions (IA) (246 IA in 157 patients) and potential contraindications (pCI) (201 pCI in 143 patients). CONCLUSION: Most identified pDRPs in cancerpatients were IAs and pCIs and involved corticosteroids. The most frequently occurring oncology-related IAs were classified as minor or moderate levels of severity.
Authors: Eric N van Roon; Sander Flikweert; Marianne le Comte; Pim N J Langendijk; Wilma J M Kwee-Zuiderwijk; Paul Smits; Jacobus R B J Brouwers Journal: Drug Saf Date: 2005 Impact factor: 5.606
Authors: Frank G A Jansman; An K L Reyners; Eric N van Roon; Carolien H Smorenburg; Helgi H Helgason; Marianne le Comte; Brigit M Wensveen; Annemieke M A van den Tweel; Mieke de Blois; Wilma Kwee; Adrian L Kerremans; Jacobus R B J Brouwers Journal: Clin Ther Date: 2011-04-02 Impact factor: 3.393
Authors: Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska Journal: J Natl Cancer Inst Date: 2007-04-18 Impact factor: 13.506
Authors: Almudena Ribed; Rosa María Romero-Jiménez; Vicente Escudero-Vilaplana; Irene Iglesias-Peinado; Ana Herranz-Alonso; Carlos Codina; Maria Sanjurjo-Sáez Journal: Int J Clin Pharm Date: 2015-12-29
Authors: Mario Occhipinti; Marta Brambilla; Giulia Galli; Sara Manglaviti; Maristella Giammaruco; Arsela Prelaj; Roberto Ferrara; Alessandro De Toma; Claudia Proto; Teresa Beninato; Emma Zattarin; Giuseppe Lo Russo; Alain Jonathan Gelibter; Maurizio Simmaco; Robert Preissner; Marina Chiara Garassino; Filippo De Braud; Paolo Marchetti Journal: J Pers Med Date: 2021-05-18